Study reveals increased hepatocellular apoptosis in pigs treated with HES 130/0.4 over Ringer’s lactate, suggesting potential hepatic risks.
Hydroxyethyl starch (HES) 130/0.4 is commonly used for volume replacement, yet its hepatic effects in the context of acute haemorrhage remain unclear. This study aimed to evaluate hepatic histopathological changes related to HES 130/0.4 administration when compared to Ringer’s lactate (RL) in healthy pigs subjected to acute bleeding under general anaesthesia. Eighteen pigs were randomised into three groups: RL (n = 6), HES 130/0.4 (n = 6), and a non-bleeding control (n = 6). Liver tissue was collected postmortem and analysed using haematoxylin–eosin staining, cytochrome c immunohistochemistry, the TUNEL assay, and M30 immunofluorescence. No statistically significant differences were observed in general histopathological changes, TUNEL, or cytochrome c expression (p > 0.050). However, the pigs that received HES 130/0.4 for volume replacement showed significantly higher intensity of the liver M30 immunostaining in the Q-score (p < 0.010), H-score (p < 0.010), and c indexc index (p < 0.050) when compared to animals that received Ringer’s lactate solution or animals in the control group. These findings suggest that HES 130/0.4 induces increased early hepatocellular apoptosis when compared to RL in this model, raising concerns about its hepatic safety profile under haemorrhagic conditions.
No takes yet. Share an insight, caveat, or question.
Vala et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: